Explore new epinephrine options—nasal spray and sublingual film—designed to boost carry-and-use rates and treat anaphylaxis faster.
David Golden, MD
Advertisement
David Golden, MD, is a clinical associate professor of medicine at Johns Hopkins University School of Medicine.
Articles by David Golden, MD
Learn severe anaphylaxis warning signs, key risk factors and how to recognize infant reactions—plus when to use epinephrine and seek ER care.
Learn why epinephrine stops anaphylaxis fast, when a second dose matters, and who can safely monitor at home after treatment.
New anaphylaxis guidance shifts care toward rapid epinephrine, fewer steroids and antihistamines, and smarter ED decisions for children and adults.
New anaphylaxis guidance urges early recognition, epinephrine-first treatment, and smarter referrals.
Advertisement
Latest Updated Articles
Epinephrine First: Closing the Anaphylaxis Gap in Primary Care PracticeFebruary 20th 2026
Identifying High‑Risk Patients and Recognizing Anaphylaxis in InfantsFebruary 23rd 2026
Advertisement
Advertisement
Trending on Patient Care Online
1
7 Drugs Approved for Primary Care: Q2 2026
2
FDA Clears OTC Adapalene-Benzoyl Peroxide Gel for Acne in Patients 12 and Older
3
FDA Clears First Generic Baloxavir for Influenza Treatment, Postexposure Prophylaxis
4
Integrating Sleep and Life’s Essential 8 Into Cardiometabolic Care, With Michael Grandner, PhD
5